Chiesi USA has announced the US launch of Bronchitol dry powder mannitol for the treatment of cystic fibrosis in adult patients. The FDA approved the Bronchitol DPI in November 2020. The company also announced the publication of data from its Phase 3 trial of Bronchitol in the Journal of Cystic Fibrosis.
Chiesi also distributes the DPI, which was developed by Pharmaxis, in eleven European countries, including Italy, the UK, Ireland, and Germany. Bronchitol was approved in Europe in 2012 and is also approved in Australia and Russia.
Chiesi USA General Manager and CEO Jon Zwinski said, “Chiesi USA has a longstanding commitment to advancing treatments and patient care programs among the CF community, and we are thrilled to add Bronchitol to our comprehensive offering. We are excited to bring the first dry powder inhaled mucoactive agent to the US for adults with CF, delivered by a portable device that doesn’t require routine maintenance or cleaning.”
Read the Chiesi USA press release.
